• Mineralys Therapeutics appointed Kristine Peterson and Lonnel Coats to its board as it prepares for lorundrostat's potential approval and commercial launch.
• Peterson most recently served as CEO of Valeritas, with earlier leadership roles at Johnson & Johnson, Biovail and Bristol-Myers Squibb.
• Coats most recently served as CEO of Lexicon Pharmaceuticals, following leadership positions at Eisai, including CEO of North America.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610191605PRIMZONEFULLFEED9848531) on October 19, 2026, and is solely responsible for the information contained therein.